Apinya Leerapun

Apinya Leerapun

Auto-generated profile, based on publicly available information

Apinya Leerapun

Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Gut and Liver
Verified
Journal Article
Open access
PDF file
KPKanokwan Pinyopornpanish
Kanokwan Pinyopornpanish
ALApinya Leerapun
Apinya Leerapun
KPKanokporn Pinyopornpanish
Kanokporn Pinyopornpanish
NCNipon Chattipakorn
Nipon Chattipakorn
Kanokwan Pinyopornpanish, Apinya Leerapun, Kanokporn Pinyopornpanish, and Nipon Chattipakorn. Gut and Liver 2021;15:827-40. https://doi.org/10.5009/gnl20367

1 February 2023 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
KPKanokwan Pinyopornpanish
Kanokwan Pinyopornpanish
ATAdisak Tantiworawit
Adisak Tantiworawit
ALApinya Leerapun
Apinya Leerapun
ASAtiwat Soontornpun
Atiwat Soontornpun
STSatawat Thongsawat
Satawat Thongsawat
Iron overload is a condition involving excessive iron deposit in various organs, the liver being the main target organ for iron deposition and overload which are associated with significant liver morbidity and mortality. Iron overload can be categorized into primary and secondary causes. Primary iron overload, so-called hereditary hemochromatosis, is a well-recognized disease with available standard treatment recommendations. However, secondary iron overload is a more diverse disease with many unclear areas to be explored. Secondary iron overload is more prevalent than primary iron overload and occurs as a consequence of various causes which differ significantly across geographic regions. The main causes of secondary iron overload are iron-loading anemias, and chronic liver disease. The liver-related outcomes, patient outcomes, and treatment recommendations in these patients differ depending on the cause of iron overload. This review summarizes the causes, pathophysiology, liver-related outcomes, disease outcomes, and treatments of secondary iron overload.

17 April 2021 in Hepatology International
Verified
Journal Article
Closed access
PDF file
ALApinya Leerapun
Apinya Leerapun
SPSiripa Puasripun
Siripa Puasripun
PKPhuripong Kijdamrongthum
Phuripong Kijdamrongthum
STSatawat Thongsawat
Satawat Thongsawat

1 May 2013
Verified
Journal Article
Closed access
ALApinya Leerapun
Apinya Leerapun
LTLakkana Thaikruea
Lakkana Thaikruea
PPPises Pisespongsa
Pises Pisespongsa
TCTaned Chitapanarux
Taned Chitapanarux
OPOng-Ard Praisontarangkul
Ong-Ard Praisontarangkul
STSatawat Thongsawat
Satawat Thongsawat

20 August 2026 in Hepatology Communications
Verified
Journal Article
Open access
WJWen Juei Jeng
Wen Juei Jeng
CCChi-Jen Chu
Chi-Jen Chu
ALApinya Leerapun
Apinya Leerapun
AAAnchalee Avihingsanon
Anchalee Avihingsanon
SZStefan Dr. Zeuzem
Stefan Dr. Zeuzem
KSKristien Swinnen
Kristien Swinnen
Background: This study assessed the safety, efficacy, and immunogenicity of a therapeutic immunization strategy aimed at reaching a functional cure for chronic hepatitis B (CHB), relying on a heterologous prime-boost with viral vectors ChAd155-hIi-HBV and MVA-HBV, combined with sequential or concomitant administration of adjuvanted recombinant HBV proteins (HBc-HBs/AS01 B ). Methods: This single-blind, randomized, controlled, first-in-human, phase 1/2 trial enrolled adults aged 18–65 years with HBeAg-negative CHB, virally suppressed on nucleos(t)ide analogs (NAs), with HBsAg >50 IU/mL. Participants received NAs and the following regimens of 4 doses (8-week intervals): sequential administration of ChAd155-hIi-HBV, MVA-HBV, and 2 HBc-HBs/AS01 B doses; co-administration of ChAd155-hIi-HBV+HBc-HBs/AS01 B , followed by 3 co-administered MVA-HBV+HBc-HBs/AS01 B doses; 4 HBc-HBs/AS01 B doses; 2 placebo doses followed by ChAd155-hIi-HBV and MVA-HBV administered alone or with HBc-HBs/AS01 B ; or 4 placebo doses. Safety, efficacy (≥1-log decrease in quantitative (q)HBsAg or HBsAg loss 24 weeks post-dose 4 [day (D)337]), antibody, and T-cell responses were evaluated. Results: In all, 134 participants were vaccinated. Grade 3 solicited adverse events (AEs) (median duration: 2–3 days) were more frequent after co-administration (systemic: 59.3%; administration-site: 33.3%) than sequential administration (systemic: 10.3%; administration-site: 12.8%) of high-dose viral vectors and proteins. No vaccine-related or fatal serious AEs were reported. After 4 doses, no participant had HBsAg loss or ≥1-log decrease in qHBsAg (D337 vs. D1). Co-administration induced the strongest anti-HBs response (73.7% achieved anti-HBs ≥10 mIU/mL 2 weeks post-dose 4 vs. 40.0% after sequential administration). Both sequential and co-administration induced HBc-specific CD4+ and CD8+ T-cell responses, with a prime-boost effect of the viral vectors. Conclusions: Heterologous prime-boost with ChAd155-hIi-HBV and MVA-HBV, combined with sequential or co-administration of HBc-HBs/AS01 B , had an acceptable safety profile, were moderately immunogenic, but no participants showed the expected efficacy outcome.